Redmile Group, LLC Adagio Therapeutics, Inc. Transaction History
Redmile Group, LLC
- $952 Million
- Q1 2025
A detailed history of Redmile Group, LLC transactions in Adagio Therapeutics, Inc. stock. As of the latest transaction made, Redmile Group, LLC holds 2,285,320 shares of ADGI stock, worth $7.56 Million. This represents 0.79% of its overall portfolio holdings.
Number of Shares
2,285,320
Previous 3,012,254
24.13%
Holding current value
$7.56 Million
Previous $9.97 Million
24.13%
% of portfolio
0.79%
Previous 0.78%
Shares
6 transactions
Others Institutions Holding ADGI
# of Institutions
85Shares Held
67.7MCall Options Held
31.6KPut Options Held
54.3K-
Mithril Ii Gp LP Austin, TX11.2MShares$37.2 Million46.08% of portfolio
-
Lee Ainslie Maverick Capital LTD | Dallas, Tx11MShares$36.3 Million0.71% of portfolio
-
Deep Track Capital, LP Greenwich, CT9.72MShares$32.2 Million1.13% of portfolio
-
M28 Capital Management LP Stamford, CT9.25MShares$30.6 Million32.33% of portfolio
-
Black Rock Inc. New York, NY4.47MShares$14.8 Million0.0% of portfolio
About Adagio Therapeutics, Inc.
- Ticker ADGI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 108,831,000
- Market Cap $505M
- Description
- Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatmen...